ObsEva Announces Second Quarter 2021 Financial Results and Business Update
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-
-Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21-
-Ebopiprant:…
